A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metastatic or Locally Advanced Solid Tumors
Phase 1
- Conditions
- CancerMedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104Therapeutic area: Diseases [C] - Neoplasms [C04]
- Registration Number
- CTIS2022-503080-15-00
- Lead Sponsor
- Kadmon Corporation LLC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular targets does KD033 (SAR445710), a PRMT5 inhibitor, modulate in metastatic or locally advanced solid tumors?
How does KD033's preliminary efficacy in phase I trials for solid tumors compare to standard-of-care treatments like chemotherapy or immunotherapy?
Which biomarkers are being evaluated in CTIS2022-503080-15-00 to predict response to KD033 in metastatic solid tumor patients?
What are the known adverse events of PRMT5 inhibitors like KD033 in phase I trials for advanced solid tumors, and what management strategies are employed?
What combination therapies involving KD033 (SAR445710) and other targeted agents are being investigated for metastatic solid tumors by Kadmon Corporation?